Search

Search Constraints

You searched for: Author/Creator Nissen, Michael J

Search Results

1. ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update. Issue 1 (21st October 2022)

2. Current differentiation between radiographic and non-radiographic axial spondyloarthritis is of limited benefit for prediction of important clinical outcomes: data from a large, prospective, observational cohort. Issue 1 (2nd February 2022)

3. Drug retention, inactive disease and response rates in 1860 patients with axial spondyloarthritis initiating secukinumab treatment: routine care data from 13 registries in the EuroSpA collaboration. Issue 3 (19th September 2020)

4. Effectiveness and treatment retention of TNF inhibitors when used as monotherapy versus comedication with csDMARDs in 15 332 patients with psoriatic arthritis. Data from the EuroSpA collaboration. Issue 11 (3rd June 2021)

5. Effectiveness of secukinumab versus an alternative TNF inhibitor in patients with axial spondyloarthritis previously exposed to TNF inhibitors in the Swiss Clinical Quality Management cohort. Issue 9 (24th June 2020)

6. Impact of discordance between patient's and evaluator's global assessment on treatment outcomes in 14 868 patients with spondyloarthritis. (20th January 2020)

7. Impaired response to treatment with tumour necrosis factor α inhibitors in smokers with axial spondyloarthritis. Issue 3 (9th February 2015)

8. Predictive value of anti-CarP and anti-PAD3 antibodies alone or in combination with RF and ACPA for the severity of rheumatoid arthritis. (27th January 2021)

9. Retention and response rates in 14 261 PsA patients starting TNF inhibitor treatment—results from 12 countries in EuroSpA. (30th October 2019)

10. Sacroiliac joint radiographic progression in axial spondyloarthritis is retarded by the therapeutic use of TNF inhibitors: 12-year data from the SCQM registry. Issue 2 (21st October 2022)